GT Apeiron Therapeutics launched by GT Healthcare Capital Partners signs with Exscientia
GT Healthcare Capital Partners ("GT Healthcare"), a life science-focused private equity partnership which specializes in capital investments and market scalability in Asia/ Greater China region, has launched an AI-driven drug development company in Shanghai with $27 million financial backing today.
SHANGHAI, June 11, 2019-- GT Apeiron Therapeutics ("Apeiron"), a novel biotechnology company, was launched with the backing from GT Healthcare and associated investors.
The company also entered into a drug discovery collaboration with Exscientia, which utilizes artificial intelligence for drug discovery. Working with Exscientia' state-of-the-art automated AI drug discovery platform and other emerging technologies, Apeiron aims to accelerate the development of novel drugs via new pathways to tackle high impact therapeutic targets, with an initial focus on oncology.
"Though pharmaceutical R&D productivity has been a challenge for the industry, we have seen positive trends such as breakthroughs in biology, novel approaches, and acceleration of technology advances. Apeiron will leverage such emerging technologies to significantly improve drug R&D productivity to benefit patients," Dr. Mingxi Li said in an interview at the launch. He is a Partner at GT Healthcare and a board member of Apeiron.
Led by a team with extensive drug discovery expertise, Apeiron intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence, which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.
"We are launching GT Apeiron at a time of rapid AI-powered tools development underpinning new drug development," said Dave Norwood, Advisory Board Chairman of Apeiron. "I am delighted to see a highly-devoted team, leveraging on latest technologies to efficiently develop new drugs tackling difficult-to-drug targets and to address huge unmet medical needs globally."
Professor Andrew Hopkins, Exscientia's CEO, commented: "This is an exciting time for pharmaceutical research, with innovative approaches to drug discovery as well as the development of new commercial markets. Both are strongly evident in China, already the second largest national pharmaceutical market in the world, where we are delighted to join our expertise and technology with GT Apeiron to initiate our first discovery opportunity in the country. The medicines we generate by applying our AI platform and GT Apeiron's experimental expertise will focus on areas of significant unmet need with global potential."
About GT Apeiron Therapeutics
GT Apeiron Therapeutics was launched in 2019 by GT Healthcare Capital Partners. It is a Shanghai-headquartered biotechnology platform utilizing state-of-the-art technologies for drug discovery.
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches. Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including Roche, Celgene, GSK, Sanofi and Evotec.
About GT Healthcare Capital Partners
GT Healthcare Capital Partners is an Asia-based private equity firm that specializes in life science investments around the globe that aim to benefit patients. GT Healthcare aims to provide capital and scale expertise to healthcare businesses in Asia / Greater China.
For more information, please contact: firstname.lastname@example.org
Venture Capital Database